Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn
Portfolio Pulse from
Stereotaxis is expected to receive FDA approval for its MAGiC system this fall, which could end its cash burn. The company has set conservative sales targets for 2025, focusing on existing system backlog and MAGiC usage in Europe. MAGiC Sweep is anticipated to generate significant recurring revenue.
March 07, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stereotaxis is on track to receive FDA approval for its MAGiC system, which could end its cash burn. The company has set conservative sales targets for 2025, focusing on existing system backlog and MAGiC usage in Europe. MAGiC Sweep is expected to generate significant recurring revenue.
The FDA approval of MAGiC is a significant milestone for Stereotaxis, potentially ending its cash burn and providing a new revenue stream. The conservative sales targets for 2025 suggest achievable growth, and the MAGiC Sweep's recurring revenue potential further strengthens the company's financial outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100